SEC Form 4 · accession 0001104659-16-107413
Corvus Pharmaceuticals, Inc. · CRVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Erik J. Verner
Officer — V.P., Chemistry Research
Period of report
Mar 22, 2016
Accepted (ET)
Mar 24, 2016 · 4:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001626971
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $15.00 | Mar 22, 2016 | A | 60,000 | A | — | Mar 22, 2026 | Common Stock | 60,000 | 60,000 | D |
Explanation of responses
- F1The underlying shares subject to the option vest and become exercisable as to one-forty-eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from March 22, 2016, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.